Our results however seem to confirm data from “real-world” clinical practice where, despite also the use of ESAs, several studies suggest that the management of anemia in advanced CKD and at dialysis initiation is suboptimal: in this setting, about 30–50% of patients have Hb < 10 g/dl25,26. Here, GSTM1 is linked to anemia (phenotype).